prostate cancer

U.S. Defense Secretary Lloyd Austin has delegated his responsibilities to his deputy as he receives treatment for a critical health issue. This development comes after Austin’s recent hospitalization for a bladder problem. What Happened: The Pentagon announced on Sunday that Austin has been...

U.S. Defense Secretary Lloyd Austin was hospitalized due to post-surgery complications arising from his prostate cancer treatment, his doctors revealed on Tuesday. What Happened: The news has caused a stir, particularly because President Joe Biden was kept in the dark about Austin’s...

Merck & Co Inc (NYSE: MRK) will stop the Phase 3 KEYLYNK-010 trial investigating Keytruda combined with Lynparza for metastatic castration-resistant prostate cancer (mCRPC). The trial included mCRPC patients who progressed after treatment with chemotherapy and either abiraterone acetate...

ViewRay Inc (NASDAQ: VRAY) has announced the first toxicity results from the Phase 2 SCIMITAR trial assessing stereotactic body radiation therapy (SBRT) in prostate cancer patients who have undergone surgery.  The first toxicity results evaluated 100 patients with recurrent...

Investigators from the University of Pittsburgh School of Medicine have published a clinical study demonstrating favorable outcomes for localized intermediate-risk prostate cancer patients treated with IsoRay Inc's (NYSE: ISR) Cesium-131 brachytherapy known as Cesium Blu....

Bellicum will issue pre-funded warrants to purchase up to 20.6 million shares and accompanying warrants to purchase up to 2.06 million shares at a combined unit price of $1.7024. Warrants have an exercise price of $1.69 per share. Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) also ...

Bayer AG (OTC: BAYRY) said a combination therapy, including its Nubeqa drug, was shown to prolong the lives of men who have metastatic prostate cancer in a clinical study. Nubeqa (darolutamide) improved overall survival in combination with standard care compared to standard care alone,...

ORIC Pharmaceuticals Inc (NASDAQ: ORIC) announced initial data from Phase 1b study evaluating ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide. Data were presented at AACR-NCI-EORTC. Related Link: Oric Pharma's ORIC-101...

Caris Life Sciences and ESSA Pharma Inc (NASDAQ: EPIX) have announced a Precision Development program to support ESSA's development of EPI-7386 in metastatic castration-resistant prostate cancer (mCRPC) failing current standard-of-care therapies. Under the terms of the...

In a spat between Takeda Pharmaceutical Co Ltd (NYSE: TAK) and AbbVie Inc (NYSE: ABBV) for Lupron (leuprorelin), a Delaware judge has issued a ruling in favor of AbbVie. The new ruling found that Takeda is guilty of breach of contract for failing to supply its partner with...

AstraZeneca Plc (NASDAQ: AZN) has reported high-level results from the PROpel Phase 3 trial of Lynparza (olaparib) in metastatic castration-resistant prostate cancer (mCRPC). The data showed Lynparza plus abiraterone demonstrated improvement in radiographic progression-free survival...

Novartis AG (NYSE: NVS) is building the case for its radioligand therapy, 177Lu-PSMA-617. With positive Phase 3 primary endpoint data in the bag, Novartis at the European Society of Medical Oncology Congress 2021 (ESMO21) presented the therapy's effect on the quality of life and pain...

MacroGenics Inc (NASDAQ: MGNX) announced preliminary safety and anti-tumor activity data from dose-expansion cohorts of the Phase 1 trial of MGC018. The data was presented at the 2021 European Society for Medical Oncology (ESMO21) Virtual Conference. Data: 39 metastatic...

Following a deeper discount, Johnson & Johnson (NYSE: JNJ) has secured reimbursement in England for its prostate cancer drug Erleada (apalutamide). Less than four months ago, the National Institute of Health and Care Excellence (NICE) rejected Erleada, even though it...

The death of a patient in a solid tumor trial hit Poseida Therapeutics Inc (NASDAQ: PSTX) hard last August, but since then, the hold has been lifted, and it is now reporting some early data from that same therapy. The Company announced interim results for P-PSMA-101, solid...